

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5587612

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
EMMA LINDEROTH	10/11/2017
NATASJA NIELSEN VILLER	10/11/2017
ROBERT ADAM UGER	10/11/2017
PENKA SLAVCHEVA SLAVOVA-PETROVA	10/11/2017
RECEIVING PARTY DATA	
Name:	TRILLIUM THERAPEUTICS INC.
Street Address:	2488 DUNWIN AVENUE
City:	MISSISSAUGA, ONTARIO
State/Country:	CANADA
Postal Code:	L5L 1J9
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16344974
CORRESPONDENCE DATA	
Fax Number:	(312)474-0448
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	312-474-6300
Email:	docket@marshallip.com
Correspondent Name:	MARSHALL, GERSTEIN & BORUN LLP
Address Line 1:	233 S. WACKER DRIVE
Address Line 2:	SUITE 6300
Address Line 4:	CHICAGO, ILLINOIS 60606
ATTORNEY DOCKET NUMBER:	32151/54216
NAME OF SUBMITTER:	DAVID A. GASS
SIGNATURE:	/David A. Gass #38,153/
DATE SIGNED:	06/24/2019
Total Attachments: 2	
source=54216_Executed_Assignment#page1.tif	
source=54216_Executed_Assignment#page2.tif	

ASSIGNMENT - Worldwide

WHEREAS we,

- 1) Emma Linderoth, of 217 Pape Avenue, Toronto Ontario M4M 2W2 Canada; and;
- 2) Natasja Nielsen Viller, of 1109 Grandeur Crescent, Oakville, Ontario L6H 4B4; and
- 3) Robert Adam Uger, of 20 Reditt Court, Richmond Hill, Ontario L4C 7S4 Canada; and
- 4) Penka Slavcheva Slavova-Petrova of 2261-1207 Lake Shore Blvd. West, Toronto, ON, M8V 3X1 Canada;

are co-inventors of an invention entitled:

ENHANCEMENT OF CD47 BLOCKADE THERAPY BY PROTEASOME INHIBITORS

for which a provisional patent application was filed in the United States Patent and Trademark Office on November 3, 2016 under serial number 62/416,936, and for which an international patent application is about to be filed under the Patent Cooperation Treaty in the Canadian Receiving Office with a priority claim to that provisional application ("the Applications");

AND WHEREAS we contributed to the invention during the course of our employment with, and for the benefit of, Trillium Therapeutics Inc., a corporation organized under the laws of the Canadian province of Ontario, having a place of business at 2488 Dunwin Avenue, Mississauga, Ontario L5L 1J9 Canada ;

NOW THEREFORE, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, we do hereby sell and assign to the said

Trillium Therapeutics Inc.

as assignee, and its successors, assigns and legal representatives, our entire right, title and interest, for all countries in and to the said invention and in and to the said Applications and any and all Letters Patent that may be obtained therefor in all countries.


AND we request that any and all Letters Patent for said invention be issued to said assignee, its successors, assigns and legal representatives, or to such nominees as it may designate.

AND we agree that when requested we will, without charge to said assignee but at its expense, sign all papers, take all rightful oaths, and do all acts which may be necessary, desirable or convenient for securing and maintaining patents for said invention, in all countries and for vesting title thereto in said assignee, its successors, assigns and legal representatives or nominees.


AND we authorize and empower the said assignee, its successors, assigns and legal representatives or nominees, to invoke and claim for any applications for patent or other form of protection for said invention filed by it or them the benefit of the right of priority provided by the International Convention for Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it and to invoke and claim such right or priority without further written or oral authorization from us, and we hereby assign to said assignee all my said right to claim priority in any country from said Applications.

AND we hereby consent that a copy of this assignment shall be deemed a full legal and formal equivalent of any assignment, consent to file or like document which may be required in any country for any purpose and particularly in proof of the right of the said assignee or nominee to claim the aforesaid benefit of priority provided by said Convention, as amended, or by any convention which may henceforth be substituted for it.


Signed at Mississauga, Canada this 11th day of October 2017.




Emma Linderoth




witness




Natasja Nielsen Villex




witness




Robert Adam Uger



witness



Penka Slavcheva Slavova-Petrova




witness

Tollium Therapeutics Inc. accepts this assignment.



Niels Stjernholm, Chief Executive Officer



witness